Published in J Immunol on June 15, 2004
Graft-versus-host disease. Lancet (2009) 8.78
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Dendritic cell homeostasis. Blood (2009) 3.18
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood (2008) 2.24
Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med (2006) 2.18
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood (2011) 1.76
Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood (2005) 1.58
Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. Blood (2012) 1.48
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood (2007) 1.37
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 1.34
Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood (2008) 1.24
Acute graft-versus-host disease: a bench-to-bedside update. Blood (2014) 1.23
A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One (2011) 1.20
CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol (2012) 1.12
Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology. Histopathology (2008) 1.11
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med (2009) 1.08
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood (2007) 1.07
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood (2012) 1.06
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res (2007) 1.06
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Langerhans cells are not required for graft-versus-host disease. Blood (2010) 1.01
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol (2014) 0.99
Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int (2011) 0.97
Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood (2008) 0.96
Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol (2012) 0.96
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev (2014) 0.93
Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation (2006) 0.90
Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood (2008) 0.90
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin Immunol (2010) 0.89
Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood (2009) 0.89
NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. Bone Marrow Res (2012) 0.89
Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant (2010) 0.88
Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. J Immunol (2015) 0.88
Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD. Blood (2014) 0.86
Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood (2014) 0.86
Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol (2013) 0.86
Treatment of graft-versus-host disease with naturally occurring T regulatory cells. BioDrugs (2013) 0.82
Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant (2012) 0.81
Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One (2013) 0.81
Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease. Biol Blood Marrow Transplant (2011) 0.81
Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin Dev Immunol (2010) 0.80
Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients. Biol Blood Marrow Transplant (2014) 0.79
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant (2015) 0.79
Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden? Bone Marrow Transplant (2015) 0.78
Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens. J Immunol (2015) 0.78
Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. J Clin Invest (2017) 0.78
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant (2016) 0.78
Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells. Immunol Cell Biol (2015) 0.77
In vivo T cell activation induces the formation of CD209(+) PDL-2(+) dendritic cells. PLoS One (2013) 0.77
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy (2010) 0.77
Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function. Blood (2006) 0.77
Mechanisms of cyclic nucleotide phosphodiesterases in modulating T cell responses in murine graft-versus-host disease. PLoS One (2013) 0.77
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. Biol Blood Marrow Transplant (2015) 0.77
Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. PLoS One (2013) 0.76
Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Trans Am Clin Climatol Assoc (2013) 0.75
Efficacy of azithromycin in preventing lethal graft-versus-host disease. Clin Exp Immunol (2013) 0.75
Disease severity and mortality can be independently regulated in a mouse model of experimental graft versus host disease. PLoS One (2015) 0.75
Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells. Immun Inflamm Dis (2017) 0.75
Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Cell Death Dis (2016) 0.75
T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. J Immunol (2016) 0.75
Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol (2017) 0.75
PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. PLoS One (2017) 0.75
Graft-versus-host disease. Lancet (2009) 8.78
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol (2011) 3.10
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Adverse functions of IL-17A in experimental sepsis. FASEB J (2008) 2.60
Safety of workers at the Fukushima Daiichi nuclear power plant. Lancet (2011) 2.60
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood (2009) 2.39
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35
Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood (2012) 2.30
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
Pathophysiology of graft-versus-host disease. Semin Hematol (2006) 2.21
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 2.21
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
Validity and reliability of a visual scoring method for masticatory ability using test gummy jelly. Gerodontology (2012) 1.99
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Identification of liver cancer-specific aptamers using whole live cells. Anal Chem (2008) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 1.88
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood (2012) 1.85
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Immunobiology of acute graft-versus-host disease. Blood Rev (2003) 1.83
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood (2013) 1.82
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood (2007) 1.79
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant (2003) 1.75
Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med (2010) 1.75
Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2011) 1.72
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.70
Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood (2013) 1.69
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol (2009) 1.65
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol (2007) 1.63
Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med (2011) 1.61
Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics (2005) 1.59
Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood (2005) 1.58
Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension (2010) 1.57
Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation. J Immunol (2006) 1.56
The pathophysiology of acute graft-versus-host disease. Int J Hematol (2003) 1.55
Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol (2005) 1.53
Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.52
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood (2005) 1.51
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood (2013) 1.50
Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica (2005) 1.50
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) (2012) 1.48
Epidemiological characterization of Streptococcus pyogenes isolated from patients with multiple onsets of pharyngitis. FEMS Microbiol Lett (2011) 1.47
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int (2012) 1.46
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J (2005) 1.46
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46